Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $30.00 at Robert W. Baird

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target reduced by investment analysts at Robert W. Baird from $60.00 to $30.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. Robert W. Baird's price target suggests a potential upside of 40.46% from the stock's current price.

A number of other analysts have also weighed in on SRPT. JPMorgan Chase & Co. lowered their price target on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating for the company in a report on Tuesday, May 20th. Guggenheim lowered their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Oppenheimer dropped their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price target (down previously from $113.00) on shares of Sarepta Therapeutics in a report on Monday. Finally, Piper Sandler cut Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $70.00 to $36.00 in a report on Monday. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $80.43.

Sarepta Therapeutics Price Performance

Shares of SRPT stock traded up $0.42 during trading hours on Tuesday, hitting $21.36. The company had a trading volume of 6,944,293 shares, compared to its average volume of 2,993,971. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of 17.05 and a beta of 0.61. Sarepta Therapeutics has a 12 month low of $18.30 and a 12 month high of $173.25. The firm's fifty day moving average is $45.69 and its 200 day moving average is $85.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company's revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 earnings per share. On average, sell-side analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC boosted its position in Sarepta Therapeutics by 16,717.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock valued at $10,602,000 after purchasing an additional 84,926 shares during the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of Sarepta Therapeutics by 1.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 33,033 shares of the biotechnology company's stock valued at $4,016,000 after purchasing an additional 335 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Sarepta Therapeutics by 5.6% during the 4th quarter. Principal Financial Group Inc. now owns 282,084 shares of the biotechnology company's stock worth $34,299,000 after buying an additional 15,047 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after buying an additional 139 shares during the period. Finally, Atria Wealth Solutions Inc. grew its stake in Sarepta Therapeutics by 10.5% in the 4th quarter. Atria Wealth Solutions Inc. now owns 11,692 shares of the biotechnology company's stock valued at $1,422,000 after buying an additional 1,108 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.